Atea sticks it out with failed COVID-19 antiviral but also raids Merck’s store room for hepatitis C drug
Atea sticks it out with failed COVID-19 antiviral but also [...]
Cytokinetics finds worldwide partner in Royalty Pharma for heart failure drug, snags up to $450M to extend runway
Cytokinetics finds worldwide partner in Royalty Pharma for heart failure [...]
AstraZeneca picks up new weapon in rare disease fight with Alnylam and Pfizer, paying $30M for rights to an early-phase asset
AstraZeneca picks up new weapon in rare disease fight with [...]
Chutes & Ladders—Maraganore’s post-Alnylam ambitions take flight
Chutes & Ladders—Maraganore’s post-Alnylam ambitions take flight fkansteiner Thu, 01/06/2022 [...]
Aligos says stop right now to lead hep B med after fruitless phase 1 data
Aligos says stop right now to lead hep B med [...]
Sanofi makes AI play, putting up $100M and billions in biobucks to form broad deal with Exscientia
Sanofi makes AI play, putting up $100M and billions in [...]
Amgen chooses Generate in $1.9B biobucks deal to churn out up to 10 multispecific drugs
Amgen chooses Generate in $1.9B biobucks deal to churn out [...]
Sanofi tears up Sangamo cell therapy deal in pivot to off-the-shelf approaches
Sanofi tears up Sangamo cell therapy deal in pivot to [...]
Novartis taps Alnylam for ambitious push to fix liver function
Novartis taps Alnylam for ambitious push to fix liver function [...]
VCs plow $115M into next-gen genetic medicine startup SalioGen, teeing up work on eye and liver diseases
VCs plow $115M into next-gen genetic medicine startup SalioGen, teeing [...]